Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Aflibercept/Sham Clear all

Conditions: Macular Degeneration
Interventions: ranibizumab, aflibercept injection (VEGF Trap-Eye, BAY86-5321); Biological
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years and older
Enrollment: 1,217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 176
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 144 more

Conditions: Wet Macular Degeneration
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 41
States / cities: Phoenix, Arizona • Mountain View, California • Sacramento, California + 36 more

Conditions: Wet Macular Degeneration
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years and older
Enrollment: 671 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 52
States / cities: Phoenix, Arizona • Tucson, Arizona • Campbell, California + 47 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: 2.0 mg OPT-302, 2.0 aflibercept, Sham; Biological · Procedure
Lead sponsor: Opthea Limited; Industry
Eligibility: 50 Years and older
Enrollment: 998 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 60
States / cities: Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 57 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: 4 mg CLS-TA, Sham, IVT aflibercept; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more

Conditions: Macular Edema Secondary to Retinal Vein Occlusion
Interventions: Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein; Drug · Diagnostic Test
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 892 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 53
States / cities: Fullerton, California • Long Beach, California • Mountain View, California + 48 more

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 81
States / cities: Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more

Conditions: Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions: VEGF Trap-Eye 2.0mg, Sham; Biological · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 46
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 41 more

Conditions: Macular Edema, Branch Retinal Vein Occlusion
Interventions: Faricimab, Aflibercept, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • Campbell, California + 36 more

Conditions: Diabetic Macular Edema
Interventions: IVT aflibercept, Sham SC, SC CLS-TA; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 29
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 25 more

Conditions: Diabetic Macular Edema
Interventions: Aflibercept, OPT-302, Sham intravitreal injection; Biological · Other
Lead sponsor: Opthea Limited; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 34
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Prompt Sham, Prompt aflibercept, Deferred laser, Deferred aflibercept; Procedure · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 81
States / cities: Phoenix, Arizona • Tucson, Arizona • Huntington Beach, California + 68 more

Conditions: Central Retinal Vein Occlusion
Interventions: Brolucizumab 6 mg, Aflibercept 2 mg, Sham injection; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 30
States / cities: Phoenix, Arizona • La Jolla, California • Mountain View, California + 24 more

Conditions: Diabetic Macular Edema
Interventions: Aflibercept, Faricimab, Sham Procedure; Drug · Procedure
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 50
States / cities: Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 44 more

Conditions: Nonproliferative Diabetic Retinopathy
Interventions: Intravitreal aflibercept injection [IAI], Sham; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 71
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 63 more

Conditions: Exudative Age-related Macular Degeneration
Interventions: 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea, sham injection; Drug
Lead sponsor: Lpath, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 44
States / cities: Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: UBX1325 injection 50 μL, EYLEA® (aflibercept) Injection 2 mg (0.05mL); Drug
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 14
States / cities: Beverly Hills, California • Huntington Beach, California • Longmont, Colorado + 11 more

Conditions: Exudative Age-related Macular Degeneration
Interventions: RBM-007 Injectable Solution, Aflibercept, Sham; Drug
Lead sponsor: Ribomic USA Inc; Industry
Eligibility: 55 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 8
States / cities: Phoenix, Arizona • Sacramento, California • Walnut Creek, California + 5 more

Search by objective public record fields.

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD)

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion

Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema

A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

Anti-VEGF Treatment for Prevention of PDR/DME

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD

Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)

A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration